MA39628B1 - Procédé de préparation d'amg 416 - Google Patents

Procédé de préparation d'amg 416

Info

Publication number
MA39628B1
MA39628B1 MA39628A MA39628A MA39628B1 MA 39628 B1 MA39628 B1 MA 39628B1 MA 39628 A MA39628 A MA 39628A MA 39628 A MA39628 A MA 39628A MA 39628 B1 MA39628 B1 MA 39628B1
Authority
MA
Morocco
Prior art keywords
amg
preparing
preparing amg
shpt
mbd
Prior art date
Application number
MA39628A
Other languages
English (en)
Inventor
Ying Chen
Jeroen Bezemer
Richard Crockett
Kevin Crossley
Sheng Cui
Liang Huang
Sian Jones
Asher Lower
Krishnakumar Ranganathan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54241346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39628(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA39628B1 publication Critical patent/MA39628B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation d'amg 416, ou d'un sel pharmaceutiquement acceptable de celui-ci. Amg 416 est un peptide agoniste sélectif de synthèse à 8 acides aminés du récepteur sensible au calcium. Il a été développé pour servir de traitement intraveineux de l'hyperparathyroïdisme secondaire (shpt) chez les patients d'hémodialyse présentant des troubles minéraux et osseux de la maladie rénale chronique (ckd-mbd).
MA39628A 2014-04-03 2015-04-03 Procédé de préparation d'amg 416 MA39628B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974899P 2014-04-03 2014-04-03
EP15773570.5A EP3126373B1 (fr) 2014-04-03 2015-04-03 Procédé de préparation d'amg 416
PCT/US2015/024347 WO2015154031A1 (fr) 2014-04-03 2015-04-03 Procédé de préparation d'amg 416

Publications (1)

Publication Number Publication Date
MA39628B1 true MA39628B1 (fr) 2020-05-29

Family

ID=54241346

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052906A MA52906A (fr) 2014-04-03 2015-04-03 Procédé de préparation d'amg 416
MA39628A MA39628B1 (fr) 2014-04-03 2015-04-03 Procédé de préparation d'amg 416

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA052906A MA52906A (fr) 2014-04-03 2015-04-03 Procédé de préparation d'amg 416

Country Status (27)

Country Link
US (3) US10407464B2 (fr)
EP (3) EP4219526A3 (fr)
JP (1) JP6710158B2 (fr)
KR (1) KR102397271B1 (fr)
CN (1) CN106795201A (fr)
AU (1) AU2015240527B2 (fr)
BR (1) BR112016022868A2 (fr)
CA (1) CA2944194C (fr)
CL (1) CL2016002513A1 (fr)
CY (1) CY1123100T1 (fr)
DK (1) DK3126373T3 (fr)
EA (1) EA032597B1 (fr)
ES (2) ES2786225T3 (fr)
HR (1) HRP20200527T1 (fr)
HU (1) HUE048489T2 (fr)
IL (1) IL248059B2 (fr)
LT (1) LT3126373T (fr)
MA (2) MA52906A (fr)
ME (1) ME03781B (fr)
MX (1) MX2016012965A (fr)
PL (1) PL3126373T3 (fr)
PT (1) PT3126373T (fr)
RS (1) RS60187B1 (fr)
SG (1) SG11201608176VA (fr)
SI (1) SI3126373T1 (fr)
WO (1) WO2015154031A1 (fr)
ZA (1) ZA201606844B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3013318T1 (sl) 2013-06-28 2017-11-30 Amgen Inc. Stabilna tekoča oblika amg 416 (velkalcetid)
CN106795201A (zh) 2014-04-03 2017-05-31 美国安进公司 用于制备amg416的方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
US11117946B2 (en) 2016-03-23 2021-09-14 Bachem Holding Ag Method for preparing glucagon-like peptides
US10858390B2 (en) 2016-09-02 2020-12-08 Cem Corporation Use of excess carbodiimide for peptide synthesis at elevated temperatures
CN108101959B (zh) * 2016-11-24 2021-07-09 四川科伦药物研究院有限公司 一种制备高纯度多肽或其类似物的方法
CN106928171B (zh) * 2017-05-03 2019-08-13 成都郑源生化科技有限公司 Fmoc-Arg（Pbf）-OH的合成方法
TW201915009A (zh) * 2017-10-03 2019-04-16 中化合成生技股份有限公司 合成依特卡肽（Ｅｔｅｌｃａｌｃｅｔｉｄｅ）或其鹽類之方法
CN110498835B (zh) * 2018-05-17 2021-06-08 深圳翰宇药业股份有限公司 一种合成etelcalcetide的方法
CN109280078B (zh) * 2018-10-30 2019-06-25 成都诺和晟泰生物科技有限公司 一种制备维拉卡肽的方法
CN112062811B (zh) * 2019-06-10 2022-03-25 深圳翰宇药业股份有限公司 一种维拉卡肽的合成方法
US20220298206A1 (en) * 2019-08-26 2022-09-22 Auro Peptides Ltd An improved process for the preparation of Etelcalcetide Hydrochloride
EP3875466A1 (fr) * 2020-03-05 2021-09-08 Fresenius Kabi iPSUM S.r.l. Procédé de synthèse de l'ételcalcétide
KR20230019120A (ko) 2020-06-03 2023-02-07 추가이 세이야쿠 가부시키가이샤 고난도 서열의 효율적 펩티드 축합법
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法
CN114524860A (zh) * 2021-12-29 2022-05-24 深圳翰宇药业股份有限公司 一种Etelcalcetide的合成方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
EP0339695A3 (fr) 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen Procédé de préparation d'un conjugué antigénique ou immunogénique ainsi que l'utilisation de tels conjugués
SE9603465D0 (sv) 1996-09-23 1996-09-23 Astra Ab New compounds
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
JP5473925B2 (ja) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
CN101250172B (zh) 2008-03-07 2012-05-02 上海瀚鸿化工科技有限公司 精氨酸双保护制备工艺
US8742028B2 (en) 2009-05-06 2014-06-03 Mallinckrodt Llc Solid support for Fmoc-solid phase synthesis of peptide acids
TWI520744B (zh) * 2009-07-29 2016-02-11 凱宜製藥股份有限公司 減少副甲狀腺素量之治療劑
EP2560491A1 (fr) * 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Agonistes opiacés périphériques et antagonistes opiacés périphériques
CA2814012A1 (fr) * 2010-09-08 2012-03-15 Fazel Shabanpoor Polypeptides de relaxine modifies
WO2013042129A1 (fr) 2011-09-23 2013-03-28 Natco Pharma Limited Procédé amélioré pour la préparation de bivalirudine
SI3013318T1 (sl) 2013-06-28 2017-11-30 Amgen Inc. Stabilna tekoča oblika amg 416 (velkalcetid)
CN106795201A (zh) 2014-04-03 2017-05-31 美国安进公司 用于制备amg416的方法
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
CN107434820A (zh) * 2017-08-07 2017-12-05 南京工业大学 一种维拉卡肽的合成方法

Also Published As

Publication number Publication date
KR102397271B1 (ko) 2022-05-16
HRP20200527T1 (hr) 2020-06-26
DK3126373T3 (da) 2020-05-04
SG11201608176VA (en) 2016-10-28
RS60187B1 (sr) 2020-06-30
JP6710158B2 (ja) 2020-06-17
US20170190739A1 (en) 2017-07-06
CN106795201A (zh) 2017-05-31
EP3126373A4 (fr) 2018-06-20
US10407464B2 (en) 2019-09-10
AU2015240527A1 (en) 2016-10-20
ES2943671T3 (es) 2023-06-15
EP3126373B1 (fr) 2020-03-04
PT3126373T (pt) 2020-04-24
EP4219526A3 (fr) 2023-08-30
EP3708576A1 (fr) 2020-09-16
CA2944194C (fr) 2022-04-19
EA032597B1 (ru) 2019-06-28
IL248059A0 (en) 2016-11-30
MA52906A (fr) 2021-04-21
CY1123100T1 (el) 2021-10-29
MX2016012965A (es) 2017-07-06
IL248059B1 (en) 2023-06-01
ES2786225T3 (es) 2020-10-09
KR20170026326A (ko) 2017-03-08
ZA201606844B (en) 2018-07-25
LT3126373T (lt) 2020-05-11
AU2015240527B2 (en) 2019-09-26
BR112016022868A2 (pt) 2018-07-03
EP4219526A2 (fr) 2023-08-02
US20230099078A1 (en) 2023-03-30
EP3708576B1 (fr) 2023-02-22
US20190352336A1 (en) 2019-11-21
EA201692001A1 (ru) 2017-02-28
JP2017511332A (ja) 2017-04-20
EP3126373A1 (fr) 2017-02-08
WO2015154031A1 (fr) 2015-10-08
HUE048489T2 (hu) 2020-07-28
IL248059B2 (en) 2023-10-01
SI3126373T1 (sl) 2020-06-30
PL3126373T3 (pl) 2020-07-27
ME03781B (fr) 2021-04-20
CA2944194A1 (fr) 2015-10-08
US11377474B2 (en) 2022-07-05
CL2016002513A1 (es) 2018-03-23

Similar Documents

Publication Publication Date Title
MA39628B1 (fr) Procédé de préparation d'amg 416
EA201790740A1 (ru) Индолкарбоксамидные соединения
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
MA37888B1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
RU2017105353A (ru) Соединения
EA201991078A1 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
BR112012016460A2 (pt) diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica.
MA40224B1 (fr) Anticorps se liant aux protofibrilles ass améliorés
BR112019007453A2 (pt) organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina
TN2017000158A1 (en) Carbazole derivatives
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
JO3738B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
TW201613591A (en) Pharmaceutical compositions comprising a DEXTROMETHORPHAN compound and QUINIDINE for the treatment of agitation in dementia
MD3593808T2 (ro) Polimeri de legare a protonilor pentru administrare orală
MA39688B1 (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
MX2020009668A (es) Métodos novedosos.
MA40082B1 (fr) Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme
EA201891710A1 (ru) Терапевтические соединения
EA201691160A1 (ru) Антагонисты s1p3
BR112017024852A2 (pt) antagonistas de receptor nk-1/nk-3 duplo para o tratamento de doenças dependentes de hormônio sexual
IL291665A (en) Inhibitors of receptor interaction with protein kinase i for the treatment of disease
MX2020013335A (es) Metodos novedosos.
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release